Evolus, Inc. (NASDAQ: EOLS) currently does not pay a cash dividend, resulting in a forward dividend yield of 0.00%. The company reinvests its operating capital into scaling its aesthetic product commercialization, expanding its medical sales force, and funding clinical research and development initiatives.